proliferation-independent GDNF-response signature that prognosed poor patient outcome and, more importantly, predicted poor response to AI treatment with the development of resistance. We validated these findings by demonstrating increased RET protein expression levels in an independent cohort of AI-resistant patient specimens. Together, our results establish GDNF-RET signaling as a rational therapeutic target to combat or delay the onset of AI resistance in breast cancer.
Introduction
Approximately 70% of breast tumors are positive for estrogen receptor alpha (ERα, called hereafter ER) expression, and the majority of these rely upon estrogen (E2)-mediated ER signaling for their growth. Endocrine therapy is the most common and effective treatment for this subset of breast cancers; targeting ER function by antagonizing binding of estrogens to the ER (selective ER modulators, e.g. tamoxifen), promoting ER degradation (selective ER downregulators, e.g. fulvestrant, also known as ICI182,780) or blocking estrogen biosynthesis (aromatase inhibitors, AIs) (1) . AIs have become the first-line treatment choice for post-menopausal women with ER+ breast cancers (2) . However, de novo or acquired AI resistance still limits their benefit for many patients. Several molecular mechanisms have been proposed to contribute to AI resistance. First, tumor cells can become hypersensitive to residual E2 and remain dependent on ER signaling for their growth (3) . Of relevance for the current study, some ER+ breast cancer cells lines cultured long-term under E2 deprivation (LTED) display ER hypersensitivity to E2, thus modeling breast cancers that have developed resistance to AI treatment (4, 5) . Second, tumor cells may escape the inhibitory effects of AIs by increasing ER activity independently of E2. This can result from EGFR, HER2 or IGF-IR overexpression (4, 6) leading to the activation of signaling cascades including the MAPK and PI3K/AKT pathways that promote ER phosphorylation, cell proliferation and cell survival (7) .
These findings highlight the concept that combining AIs with therapies targeting signaling pathways that interact with ER is a strategy to enhance AI therapy 5 improved progression-free survival compared to exemestane alone in patients with ER+ advanced breast cancer previously treated with the AIs letrozole or anastrozole (10). However, despite the positive outcome of such trials, many patients fail to benefit from these combined therapeutic approaches. As a consequence there remains an urgent need to better understand the mechanisms of AI resistance, and to find and develop appropriate and more efficient therapeutic strategies.
Expression of the receptor tyrosine kinase RET (REarranged during
Transfection) and its co-receptor GFRα1 (glycosyl phosphatidylinositol anchored GDNF family α-receptor-1) are low in normal breast but upregulated in a subset of ER+ breast cancers (11-13). Moreover, we have previously demonstrated that the RET ligand glial cell derived neurotrophic factor (GDNF) is upregulated by inflammatory cytokines and is expressed on infiltrating stromal fibroblasts and to a lesser extent by tumour cells in xenograft models (11). In RET+ ER+ breast cancer cells, GDNF stimulation results in an E2-independent increase in ER phosphorylation and transcriptional activity (13). However, little is known about the transcriptional program associated with GDNF-RET signaling in breast cancer cells or the relevance of this pathway to human disease. In particular, a role for GDNF-RET signaling in response and resistance to AI treatment has yet to be explored. In this study, we have identified a GDNF response gene set (RGS) with prognostic and predictive value in breast cancer, and demonstrate the utility of targeting GDNF-RET signaling in the context of AI treatment. Data were extracted using BeadStudio (Illumina) software and were transformed and normalized using variance-stabilizing transformation and robust spline normalization method in the Lumi (2.6.0) package in R (http://www.bioconductor.org). Probes were discarded if they were not detected in any of the samples (detection p>0.01).
Microarray data have been submitted to ArrayExpress database (E-MEXP-3662). To identify genes significantly regulated by GDNF treatment, a confidence score (CS) (15, 16) was calculated for each gene at each time point of GDNF treatment. CS was defined as the sum of individual scores given for fold change (FC), p-value (PV), expression level (EL), and present calls (PC).
Analysis of clinical datasets
Breast cancer subtypes in the NKI295 and Pawitan datasets were as reported by the authors. In TransBig dataset, the subtypes were retrieved and classify using PAM50 from ROCK (17) . An unscaled GDNF-RGS score that recapitulates the degree of similarity to MCF7 cells upon GDNF treatment was generated as described previously (18) . Thus, a high tumor GDNF-RGS score corresponds to a signature highly concordant with GDNF-activation in MCF7 cells.
Kaplan-Meier analysis and multivariate Cox proportional hazard regression analysis were carried out with the survival (2.36-12) and survplot (0.0.6) packages in R. GDNF-RGS positive and negative tumors were classified using the centroid Spearman correlation method with the nearest centroid >0.1 as described previously (19) . The sample was not assigned if the correlation was 0.1. 
Correlation of GDNF-RGS with response to letrozole
The cohort of patients treated with neoadjuvant letrozole has been described previously (20) . Briefly, core biopsies from ER+ tumors were collected pre-and post-14 days letrozole treatment and subject to gene expression analysis. Response was classified based on tumor volume reduction after 3 months letrozole treatment as assessed by ultrasound. Patients with >50% reduction in tumor volume were considered responders. Follow-up data were available for 52 of the 58 patients. To examine the association between the GDNF-RGS, the log2 intensity (mediancentered) of the 53 out of 67 GDNF-RGS genes available in the dataset were extracted using the ROCK database. When multiple probe sets mapped to the same gene, the one with the highest variance in the dataset was selected.
Statistical analysis
Statistical analysis was performed using GraphPad Prism Software as reported in the (Fig. 1A) and do not respond to GDNF/GFRα1 treatment ( Supplementary Fig. S1B ). RET expression can be regulated by ER activation (12, 23) and in the in vitro cell models employed here, RET expression levels mirror the levels of ER expression (Fig. 1A) .
Moreover, when parental MCF7 cells are cultured in the presence of E2, RET expression is enhanced and this can be blocked by ICI182,780 treatment, that targets ER for proteasomal degradation (Fig. 1B) . MCF7-LTED cells are hypersensitive to residual E2 (4, 5) and in the absence of exogenously added E2, a higher level of RET expression is observed (Fig. 1A and B) . E2-mediated ER activation in these cells again results in increased RET expression that can be blocked by ICI182,780 treatment (Fig. 1B) . As the majority of the breast tumors that display endocrine therapy resistance retain ER expression, we employed MCF7-LTED cells to investigate GDNF-RET signaling in the context of AI resistance. The increased RET expression in MCF7-LTED cells is mirrored by enhanced GDNF-RET downstream signaling including increased ER activation monitored by Ser167 and Ser118 phosphorylation (24) (Fig.   1C ) and transcriptional upregulation of E2-dependent genes TFF1 and PGR (Fig.   1D) . Notably, the upregulation of TFF1 and PGR, but not that of the ER-independent gene EGR1, is inhibited in the presence of ICI 182,780. Consistent with their higher levels of RET expression and more sustained GDNF-induced RET signaling, MCF7-LTED cells show increased GDNF-induced transcriptional activation compared to MCF7 cells (Fig. 1D ).
NVP-BBT594 impairs GDNF-RET signaling and GDNF-dependent growth of

MCF7-LTED cells.
Blocking RET with nM concentrations of the RET inhibitor NVP-BBT594 ( Fig. 2A is significantly reverted by NVP-BBT594 ( Figure 2C ). Conversely, consistent with their low-level ER and RET expression (Fig. 1A,B ), T47D-LTED and ZR75-1-LTED cells do not respond to GFRα1/GDNF stimulation and are minimally respond to the presence of E2 (Fig. 2C,D, Supplementary Fig. S1C ). Importantly, NVP-BBT594 has no significant impact on T47D-LTED and ZR75-1-LTED 3D colony formation demonstrating that the effects observed in MCF7-LTED cells are due to selective RET inhibition by NVP-BBT594 rather than off-target toxicity.
GDNF-promoted AI resistance can be reverted by RET inhibition
To assess further the effect of GDNF signaling in the response and adaptation to AI (Fig. 3C) , and the RET inhibitor NVP-BBT594 impairs GDNF-mediated RET downstream signaling ( Supplementary Fig. S2E ) and significantly enhances the antiproliferative effects of letrozole (SF 50 = 2.9 nM) (Fig.   3C ). Of note, the effect of GDNF on MCF7-2A cells is more pronounced when cells are cultured in 3D (Fig. 3D ). In these experimental conditions that better mimic in vivo tumor growth, GDNF promotes colony formation both in the absence and presence of letrozole, while NVP-BBT594 completely abrogates this GDNF-induced resistance (Fig. 3D ).
Identification of GDNF response genes in breast cancer cells
The preclinical in vitro models described here, together with our previous findings (13), suggest that increased RET expression and activation in ER+ breast cancers can promote resistance to endocrine therapy. However, the transcriptional program induced by GDNF-RET signaling in ER+ breast cancer cells and in particular the role of GDNF-induced ER-dependent versus ER-independent signaling in response to endocrine therapy is unknown. To address this, E2-deprived MCF7 cells were pretreated with or without ICI182,780 that targets ER for proteasomal degradation and thereby blocks expression of ER-dependent genes ( Supplementary Fig. S3A ).
Cells were then GDNF stimulated for 0, 4, 8, 24 or 48 hours and RNA from 3 independent experiments was subject to gene expression profiling. Hierarchical cluster analysis shows that the samples divide into ICI182,780 treated and untreated groups and that within these two groups, the samples cluster according to early (4 -8 hr) and late (24 -48 hr) GDNF response ( S3B ).
Gene set enrichment analysis (GSEA) was applied to identify gene sets correlated with GDNF treatment in the presence or absence of ICI182,780
(Supplementary Table S1A ). Many of the identified gene sets are related to response to serum, metabolic and apoptosis pathways, DNA damage and immune response pathways. Importantly, no correlation was found between the GDNF regulated genes in MCF7 cells and other growth factor response gene sets indicating that GDNF regulated genes do not have a substantial overlap with other growth factor signaling pathways.
To detect genes significantly regulated by GDNF a confidence score (CS) was Table S1C ).
A comparison of the gene expression profiles in the presence and absence of ICI182,780 revealed that 42 out of 50 (84%) and 18 out of 33 (54.5%) of GDNF upregulated and downregulated genes, respectively, were fully or partially dependent on ER (Fig. 4C) . A comparison of GDNF-regulated genes with a comprehensive E2-regulated gene dataset (25) revealed that not all of the GDNF/ER-dependent genes are reported to be E2-dependent (Fig. 4C ). This suggests that GDNF treatment can promote ER-mediated transcription of a subset of genes that are independent of the 
canonical E2 pathway involving estrogen response element sites. This is consistent with a previous study (26) that reported a subset of EGF-induced ER genomic targets that are distinct from those induced by E2 (see Discussion).
A proliferation-independent GDNF-response gene set (RGS) positivity correlates with poor clinical outcome
It is well established that proliferation related genes can dominate gene expression signatures, which de facto identify highly proliferative tumors (27) . Consequently, the 83 GDNF-dependent gene list was robustly filtered (Supplementary Fig. S4 ). First, all potential proliferation related genes based on GO analysis were removed. Second, genes previously reported in two independent proliferation metagene signatures were removed (28, 29) . Finally, the remaining 69 genes were correlated to Ki67 protein levels and TOP2A expression in a dataset of 81 ER+ breast cancers (30) .
Genes that showed r s >0.5 or r s <-0.5 were removed to generate the final GDNFresponse gene set (RGS) comprising 67 proliferation-independent genes ( Fig. 4B and Supplementary Table S1 ). The proliferation-independent GDNF-RGS is largely populated by GDNF late response genes and, as a result, the GDNF-RGS score is higher in the samples treated with GDNF for 24 -48 hours (Fig. 4D) . ICI182,780 has a significant impact on the GDNF-RGS score as 54 out of 67 of the GDNF-RGS genes are ER-dependent (Fig. 4C) . However, samples that were GDNF-treated in presence of ICI182,780 for 24 -48 hours show a higher GDNF-RGS score than untreated samples (without GDNF and without ICI182,780 pretreatment) indicating that GDNF-dependent ER-independent genes are accounted for within the GDNF-RGS score (Fig. 4D) . 
Bonferroni-corrected analysis showing that GDNF-RGS score is higher in luminal B than in luminal A tumors in all 3 datasets analyzed (Fig. 5A p<0.001; Fig. 5B p<0.05 ; Fig. 5C p<0.001) (32-34) . Further, analysis of 597 breast cancer samples from TGCA (http://cancergenome.nih.gov) using the ROCK database (17) shows that amongst the 5 intrinsic breast cancer subtypes, expression of the RET ligand GDNF is highest in the luminal B subtype (SAM score = 0.007, q-value = 0.02). Within ER+ breast cancers, luminal B tumors are characterized by poorer prognosis when compared to luminal A tumors (35) indicating that the GDNF-RGS and expression of GDNF associate with a clinically relevant molecular subtype of breast cancer. Consistent with this, using the nearest centroid method (19) , GDNF-RGS positivity in ER+ cancers significantly associates with a decrease in distant metastases free survival (DMFS) (Fig. 5A -right panel) and in relapse free survival (RFS) (Fig 5B and C - Fig. S6 ).
Importantly, multivariate Cox analysis reveals that the GDNF-RGS has an independent prognostic value in all three datasets analyzed (Table 1, Supplementary   Fig. S6 ). Finally, these analyses indicate that patients bearing tumors characterized by active GDNF signaling have a significantly worse outcome either in the presence (NKI295, Pawitan) or absence (TransBig) of adjuvant treatment (Fig. 5, Table 1 ).
GDNF-RGS correlates with response to aromatase inhibitor treatment
We next evaluated whether the GDNF-RGS correlates with response to AI treatment by retrieving gene expression data from biopsies of 52 ER+ breast cancers taken before and after 2 weeks of neoadjuvant letrozole treatment (20) . The patients were subsequently divided into responder and non-responder groups defined by a >50% and <50% reduction, respectively, in tumor volume following a further 3 months of AI treatment. Pairwise comparison shows a significant decrease in GDNF-RGS score after 2 weeks of letrozole treatment in the responder cohort (p=0.009) but not in the non-responder cohort (p=0.804) (Fig. 6A ).
To validate these findings, we examined the effect of the nonsteroidal AI anastrozole on the GDNF-RGS score using gene expression data and Ki67 staining available for 69 paired ER+ tumors biopsies taken pre-and post-2 weeks of neoadjuvant anastrozole treatment (30) . In such studies, a lack of response to AI treatment as monitored by a decrease in Ki67 staining has been shown to predict poor long-term disease outcome (1). The GDNF-RGS score does not correlate with levels of Ki67 in the pre-treatment samples ( Supplementary Fig. S7A -C) consistent with the absence of proliferation related genes within the GDNF-RGS. However, this pre-treatment GDNF-RGS score shows a relatively weak but statistically significant correlation with the proportional two-week change in Ki67 (r s =-0.24, p=0.047) (Supplementary Fig. S7A ). Furthermore, the change in GDNF-RGS score in the pre- Fig. S7B,C) . These data support the concept that GDNF-RET signaling plays an important role in the response and adaptation of breast cancer patients to AI treatment. Conversely, GDNF-RGS did not stratify for outcome in ER+ breast cancer patients that had exclusively received tamoxifen as adjuvant therapy ( Supplementary Fig. S7D,E ). This suggests that the different mechanism of action of AI and tamoxifen in breast cancer may influence the ER-dependent GDNF-mediated transcriptional profile.
RET expression increases in AI-resistant breast cancers
GDNF exerts its function as a ligand for the RET receptor tyrosine kinase (36) . We GDNF transcriptional profile and demonstrate that this correlates with worse prognosis and poor response to AI treatment in breast cancer patients.
A major concern in the generation of growth factor gene response signatures is that the signature can be dominated by proliferation related genes. As extensively reported, proliferation related gene signatures correlate with higher proliferating and higher grade tumors, and consequently with poor prognosis (27) . GDNF is a weak mitogen for breast cancer cells (11, 12) but interrogation of the gene expression data shows that the GDNF induced transcriptional program included serum and other mitogen response pathways (Supplementary Table 1A, C). As a consequence, the initial list of 83 genes significantly regulated by GDNF with a CS 11 was subject to robust filtering to remove 16 proliferation related genes ( Supplementary Fig. S4 ) to generate a 67 gene GDNF-RGS. The effectiveness of this approach is evidenced by the lack of correlation of the GDNF-RGS with levels of Ki67 staining and TOP2A expression in primary tumor samples (Supplementary Fig. S4 ). Further, the absence of proliferation genes within the GDNF-RGS has important implications for the observation that the GDNF-RGS associates with the luminal B subgroup of breast cancers Clinically, luminal B tumors have a poorer prognosis compared to luminal A tumors with an increased risk of early relapse with endocrine therapy and increased resistance to chemotherapy (31, 38) . The data presented here suggest that the GDNF-mediated RET signaling in breast cancer cells triggers a transcriptional program associated with a more aggressive tumor phenotype independently of pro- CAN-12-4265 mitogenic effects. Importantly, we demonstrate that the GDNF-RGS significantly correlated with a decrease in DMFS and in RFS (Fig. 5) in breast cancer patients.
Although a demonstration of prognostic value is of interest, more importantly this study revealed that a GDNF-RGS score is predictive for response to AI treatment in two independent studies (Fig. 6A and Supplementary Fig. S7A-C) . Moreover, the correlation of the change in GDNF-RGS and the change in proliferation index of the tumors indicates that activation of GDNF signaling is also associated with the response to AI treatment. Clues as to the mechanism by which GDNF-RET signaling may promote the response and adaptation of breast cancers to AI treatment has come from taking a global approach to examine GDNF-RET signaling in breast cancer cells. First, this study has revealed that GDNF can promote both E2-independent activation of ER ( Fig. 2 and 3 ) and a non-canonical ER transcriptional program (Fig. 4C) . Promotion of a non-canonical ER cistrome has been reported in breast cancer cells following EGF stimulation in a process dependent on the transcription factor AP-1 (26) . It is of note that GDNF-stimulation of MCF7-2A cells activates c-Jun (Fig. 3B) , a key component of the AP-1 complex. Second, the GDNF-RGS is enriched with genes related to immune response pathways, in particular STAT1 target genes (Supplementary Table 1, Fig. 4B ). STAT1 mediates the inflammatory response of interferon (IFN). IFN-related genes, such as ISG15, OAS1, IFI27 and OAS3 that are present in the GDNF-RGS, have been associated previously with radiation and chemotherapy resistance in breast and other cancers (39) (40) (41) . Similarly, Dunbier and colleagues have identified an inflammatory gene expression signature associated with poor response to neoadjuvant AI treatment (30) . In contrast to these reports, others have shown that an immune related signature is associated with better prognosis in triple negative and HER2+ breast cancers (28, 42) and that the presence of tumor-associated lymphocytes predicts good response to chemotherapy (43) and good clinical outcome in ER-cancers (44) . 
different breast cancer subgroups and in the response to different therapeutic regimes. What is notable in this study is that the GDNF-RGS was derived from the MCF7 experimental model rather than from tumor specimens containing both tumor and stromal cells. This suggests that within the GDNF-RGS-positive tumors, the tumor cells are actively involved in the immune response. We have previously demonstrated that GDNF is secreted in response to pro-inflammatory cytokines by both tumor cells and stromal fibroblasts (11). This raises the possibility that GDNFmediated upregulation of immune response pathways can reinforce GDNF signaling to promote cell survival in the AI resistant setting.
Despite the ability to identify breast cancer subsets, predict disease outcome and/or response to therapies (45, 46) , there is still a lack of well defined targets causally associated with resistance to endocrine therapy that can be translated into the clinic. In recent years a number of studies have provided evidence that activation of growth factor signaling pathways could be a significant contributor to the luminal B phenotype of ER+ breast cancers. In particular ERBB2 and EGFR (4, 47) , IGF-1R (48), FGFR (49) and more recently RET (13) and PDGFR (37) have been identified as potential targets in ER+ breast cancer (38) . Given the plethora of growth factor signaling pathways that can impact upon ER, it has been considered desirable to Here we demonstrate, using a multidisciplinary approach, that GDNF-RET signaling is an important determinant of AI therapy response and resistance in ER+ breast cancers. The priority now is to determine whether RET inhibition is achievable in the clinical setting to prolong the efficacy of AIs in recurrent and/or metastatic disease and whether targeting growth factor signaling pathways in combination with an AI could prevent or delay the onset of AI resistance.
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